Abstract
To evaluate the therapeutic efficacy of REBACIN® in patients with persistent high-risk HPV (hrHPV) infection. Persistent hrHPV infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. A retrospective analysis and a meta-analysis were carried out. The retrospective analysis included 364 patients who were persistently infected with HPV for at least 12months, between September 2015 and February 2019, and only received the REBACIN® intervention. HPV DNA typing, HC2 hrHPV DNA, and ThinPrep cytologic tests were performed before and after the REBACIN® intervention, to evaluate the therapeutic efficacy. The meta-analysis included trials evaluating the therapeutic efficacy of interferons. After a follow-up period of 3-6months, the overall rate of efficacy of REBACIN® was 74.73% (272/364), which was higher than that of interferon (61.50%). The efficacy of REBACIN® was correlated with HPV type (odds ratio [OR] 0.549, 95% confidence interval [CI] 0.367-0.822, P=0.004) and pretreatment cytology (OR 0.358, 95% CI 0.173-0.739, P=0.005). REBACIN® is potently efficacious at clearing persistent hrHPV infection; hence, it can serve as an optional intervention for persistent hrHPV infection.
Highlights
Persistent high-risk human papillomavirus infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable
REBACIN® is potently efficacious at clearing persistent high-risk human papillomavirus (hrHPV) infection; it can serve as an optional intervention for persistent hrHPV infection
The infection normally regresses within twenty-four months, even in the case of infection with high-risk Human papillomavirus (HPV) genotypes which were proven to be closely correlated with cervical cancer
Summary
Persistent high-risk human papillomavirus (hrHPV) infection is a crucial cause of cervical cancer, for which optimal pharmacological intervention remains unavailable. It is estimated that nearly 80% of the sexually active women are infected by HPV by the age of fifty years [3]. The infection normally regresses within twenty-four months, even in the case of infection with high-risk HPV (hrHPV) genotypes which were proven to be closely correlated with cervical cancer. Persistent hrHPV infections will increase the risk of precancerous and cancerous lesions, especially when over twelve months. A study showed that women with persistent hrHPV infections would either be free of infection or develop cervical intraepithelial neoplasia (CIN) 2 + within six years, whatever with or without intensive clinical follow-up. More efficient interventions for persistent hrHPV infections are needed to prevent progression
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
